Home > Riviste > Italian Journal of Vascular and Endovascular Surgery > Fascicoli precedenti > Italian Journal of Vascular and Endovascular Surgery 2008 March;15(1) > Italian Journal of Vascular and Endovascular Surgery 2008 March;15(1):29-37

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEWS   

Italian Journal of Vascular and Endovascular Surgery 2008 March;15(1):29-37

Copyright © 2008 EDIZIONI MINERVA MEDICA

lingua: Inglese

Targeted renal therapy for contrast-induced nephropathy prevention and renal function preservation during vascular and endovascular procedures: a systematic review

Allie D. E., Patlola R. R., Hebert C. J., Ingraldi A., Lirtzman M. D., Wyatt C. H., Walker C. M.

Cardiovascular Institute of the South Lafayette, Louisiana, US


PDF


Targeted renal therapy (TRT) is a novel emerging treatment where high-dose fenoldopam (FEN), a selective renal dopamine-1 receptor agonist and renal arteriolar vasodilator, is infused into both renal arteries via the US Food and Drug Administration (FDA)-approved 5-Fr bifurcated Benephit PV Catheter Infusion System. TRT has been shown to significantly increase the glomerular filtration rate by 25% vs placebo and IV-FEN (P<0.001), which may have important clinical implications in contrast-induced nephropathy prophylaxis and during vascular and endovascular surgical procedures.

inizio pagina